Pharma Focus Asia
KP - Choose our fully recyclable blister films

Indian Pharma

The Discovery Metamorphosis

With 60 NCEs in the pipeline, the Indian pharma has adopted the innovation path with enthusiastic diligence. More than a dozen Indian companies are now focussing on novel drug discovery and taking different routes viz. partnering with international pharma companies, outlicensing, researching collaboratively with government and academic institutions etc. There is little doubt that “drug discovery” has become the buzzword in the Indian pharmaceutical industry. Pharma Focus Asia invited top industry leaders to give their views on the same. Swati A. Piramal, Director - Strategic Alliances & Communications, Nicholas Piramal India Limited (NPIL), Glenn Saldanha, CEO, Glenmark Pharmaceuticals Ltd., Somesh Sharma, CSO, NPIL and Utkarsh Palnitkar, National Leader, Health Sciences Industry Practice, Ernst & Young, India give insights on the reasons, strategies, challenges and opportunities for Indian pharma to embark into the drug discovery era.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024